The suppression of excessive immune responses by infusion of regulatory T cells would require a product of high purity, adequate ex vivo expansion and functional stability. A description of the process to obtain an autologous cell product fulfilling these characteristics paves the way to develop clinical trials in humans.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Identification of 14-dehydroergosterol as a novel anti-inflammatory compound inducing tolerogenic dendritic cells
Scientific Reports Open Access 24 October 2017
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Pellerin, L., Jenks, J. A., Begin, P., Bacchetta, R. & Nadeau, K. C. Regulatory T cells and their roles in immune dysregulation and allergy. Immunol. Res. 58, 358–368 (2014).
Yuan, X., Cheng, G. & Malek, T. R. The importance of regulatory T-cell heterogeneity in maintaining self-tolerance. Immunol. Rev. 259, 103–114 (2014).
Sakaguchi, S. et al. Foxp3+ CD25+ CD4+ natural regulatory T cells in dominant self-tolerance and autoimmune disease. Immunol. Rev. 212, 8–27 (2006).
Marek-Trzonkowska, N. et al. Therapy of type 1 diabetes with CD4+CD25highCD127-regulatory T cells prolongs survival of pancreatic islets—results of one year follow-up. Clin. Immunol. 153, 23–30 (2014).
Trzonkowski, P. et al. Firstinman clinical results of the treatment of patients with graft versus host disease with human ex vivo expanded CD4+CD25+CD127- T regulatory cells. Clin. Immunol. 133, 22–26 (2009).
Canavan, J. B. et al. Developing in vitro expanded CD45RA+ regulatory T cells as an adoptive cell therapy for Crohn's disease. Gut http://dx.doi.org/10.1136/gutjnl2014306919.
Jostins, L. et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 491, 119–124 (2012).
Desreumaux, P. et al. Safety and efficacy of antigen-specific regulatory T-cell therapy for patients with refractory Crohn's disease. Gastroenterology 143, 1207–1217.e1–e2 (2012).
Koreth, J. et al. Interleukin-2 and regulatory T cells in graftversushost disease. N. Engl. J. Med. 365, 2055–2066 (2011).
Matsuoka, K. et al. Low-dose interleukin-2 therapy restores regulatory T cell homeostasis in patients with chronic graftversushost disease. Sci. Transl. Med. 5, 179ra43 (2013).
Acknowledgements
The authors' work is largely supported by grants SAF2012/33560 to J.P., BFU2012/35999 and a grant from the Leona and Harry Helmsley Trust to A.S.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
J.P. serves as a member of the data safety and monitoring board for Tigenix. A.S. declares no competing interests.
PowerPoint slides
Rights and permissions
About this article
Cite this article
Salas, A., Panés, J. Regulatory T cells for treatment of Crohn's disease. Nat Rev Gastroenterol Hepatol 12, 315–316 (2015). https://doi.org/10.1038/nrgastro.2015.68
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrgastro.2015.68
